

PHARMACEUTICAL 2023

Innovation1 Biotech Inc. Rank 355 of 446









PHARMACEUTICAL 2023



Innovation1 Biotech Inc. Rank 355 of 446

The relative strengths and weaknesses of Innovation1 Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Innovation1 Biotech Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 341% points. The greatest weakness of Innovation1 Biotech Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 141% points.

The company's Economic Capital Ratio, given in the ranking table, is -85%, being 128% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	287
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	29,812
Liabilities, Non-Current	11,298
Other Assets	43,674
Other Compr. Net Income	0
Other Expenses	40,466
Other Liabilities	0
Other Net Income	-152
Other Revenues	0
Property and Equipment	2.6
Research and Development	201
Selling, General and Administrative Expense	362

Output Variable	Value in 1000 USD
Assets	43,963
Liabilities	41,111
Expenses	41,030
Revenues	0
Stockholders Equity	2,853
Net Income	-41,182
Comprehensive Net Income	-41,182
Economic Capital Ratio	-85%

